ArticleEuropean journal of medical research2026
CORT silencing impairs migration and invasion: validation of a glycosylation-based risk model (CORT/LPAR5/CEBPA/MYH10/MAGEA11) in osteosarcoma.
Article in European journal of medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exploring the mechanism by which triphenyl phosphate promotes malignant phenotypes in bladder and kidney cancer through MMP9 based on bioinformatics analysis and experimental validation.Clinical and experimental medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOsteosarcoma (OS) is a bone malignancy among adolescents with a poor prognosis. We aimed to explore the glycosylation-related features in OS.
methodsA sum of 185 glycosylation-related genes (GRGs) and the RNA-seq data were obtained from the TARGET database. ConsensusClusterPlus package was applied for the various subtypes based on the significant prognostic factors. Subsequently, the limma R package performed the Lasso analysis for a RiskScore model. The survminer package conducted Kaplan-Meier (KM) analysis, and the timeROC package was used for the classifier efficiency. In addition, the ssGSEA method and MCPcounter performed the immune infiltration analysis. Finally, the expression of the selected key genes, as well as their migration and invasion capabilities, were evaluated through PCR, wound healing, and transwell assays, respectively.
resultsHigh GRG score was associated with poor prognosis. Unsupervised clustering based on prognostic GRGs identified two subtypes (C1/C2), with C1 showing worse outcomes. A prognostic RiskScore model comprising CORT, LPAR5, CEBPA, MYH10, and MAGEA11 was constructed from subtype-specific differentially expressed genes. The model effectively stratified patients into high- and low-risk groups in both training and validation cohorts, with high-risk patients exhibiting significantly shorter survival. RiskScore is an independent prognostic factor, with lower infiltration levels of cells such as macrophages and NK cells observed in patients within the high-risk group. In external immunotherapy cohorts, high-risk patients had poorer survival and treatment response. Functionally, silencing the key model gene CORT impaired osteosarcoma cell migration and invasion in vitro.
conclusionsWe developed a useful risk model and this study provided new insights for OS therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.